News

The new agreement provides unlimited access to Amerinet’s national portfolio of product and service contracts and proprietary Total Spend Management tools designed to ensure health care providers maximize

The MAA for dapoxetine was submitted under the decentralized procedure, in which Sweden will act as the reference member state and Austria, Finland, Germany, Italy, Portugal and Spain

The Phase I trial is a multi-center, open-label, sequential dose-escalation study that will enroll 20-40 patients with relapsed or refractory acute myeloid leukemia (AML). The preliminary clinical data

In the Activate Phase IIa study, CDX-110 treated Glioblastoma Multiforme (GBM) patients showed a median survival time of 30 months, more than a 100% increase in survival, versus

This open label dose escalation safety study will consist of two parts. In part I, 26 to 62 patients will be enrolled depending on the number of dose

The Phase I study was designed to assess the safety of AVE9633 when administered on days 1 and 8 of a 28-day cycle. Increasing doses of the compound

Under the agreement, Pharmetics will acquire the assets, including equipment, facilities and land, at Patheon’s facilities in Fort Erie and Burlington in Ontario. Pharmetics will provide employment to

In addition to safety and tolerability assessment, Nventa will also collect immunological data from these patients at the end of each cohort that may provide an early indication

Data from the Record1 study show that rivaroxaban demonstrated a 70% relative risk reduction (RRR) in total venous thromboembolism (VTE) when compared with enoxaparin, and an 88% RRR